Expression of eIF4E Gene in Glioma and Its Sensitivity to Oxidative Stress

Liang, Jian; Yang, Yaoqiang; Li, Xing; Cai, Guangmou; Cao, Jianxuan; Zhang, Bo

doi:10.1155/2022/5413035

Cited by 3 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The involvement of eIF4E and phosphorylated eIF4E in Ser209 (p-eIF4E) in brain carcinogenesis of different tumor types is well established ( Table 1 ). In GB ( Figure 4 ), Western blot and immunohistochemistry analyses showed that eIF4E and p-eIF4E were overexpressed in proliferative endothelial and vascular GB cells, as well as in lower-grade glioma, which is in most cases associated with adverse patient prognosis ( Gu et al, 2005 ; Yang et al, 2007 ; Tejada et al, 2009 ; Martínez-Sáez et al, 2016 ; Liang et al, 2022 ). Moreover, overexpression of Cyclin D1 strongly correlated with p-eIF4E levels in GB (Tejada 2009).…”

Section: Translation and Gb In The Spotlightmentioning

confidence: 99%

“…Moreover, overexpression of Cyclin D1 strongly correlated with p-eIF4E levels in GB (Tejada 2009). Accordingly, knocking down eIF4E led to a decrease in GB U251 cells’ capacity to proliferate and migrate and an increase in apoptosis ( Liang et al, 2022 ). Thus, the potential value of p-eIF4E as a diagnostic tool in GB biopsies has also been proposed ( Martínez-Sáez et al, 2016 ).…”

Section: Translation and Gb In The Spotlightmentioning

confidence: 99%

See 1 more Smart Citation

The dark side of mRNA translation and the translation machinery in glioblastoma

Montiel-Dávalos

Ayala²,

Hernández³

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on tumor resection, radiation, and chemotherapies. The current development of novel molecular biomarkers (MB) has led to a more accurate prediction of GB progression. Moreover, clinical, epidemiological, and experimental studies have established genetic variants consistently associated with the risk of suffering GB. However, despite the advances in these fields, the survival expectancy of GB patients is still shorter than 2 years. Thus, fundamental processes inducing tumor onset and progression remain to be elucidated. In recent years, mRNA translation has been in the spotlight, as its dysregulation is emerging as a key cause of GB. In particular, the initiation phase of translation is most involved in this process. Among the crucial events, the machinery performing this phase undergoes a reconfiguration under the hypoxic conditions in the tumor microenvironment. In addition, ribosomal proteins (RPs) have been reported to play translation-independent roles in GB development. This review focuses on the research elucidating the tight relationship between translation initiation, the translation machinery, and GB. We also summarize the state-of-the-art drugs targeting the translation machinery to improve patients’ survival. Overall, the recent advances in this field are shedding new light on the dark side of translation in GB.

show abstract

Section: Translation and Gb In The Spotlightmentioning

confidence: 99%

Section: Translation and Gb In The Spotlightmentioning

confidence: 99%

The dark side of mRNA translation and the translation machinery in glioblastoma

Montiel-Dávalos

Ayala²,

Hernández³

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…eIF4E is upregulated in many tumours 16–18 and is an important oncogenic factor with therapeutic promise. eIF4E's only known post‐translational modification is phosphorylation at its S209 site, downstream of MNK1/2 19 .…”

Section: Introductionmentioning

confidence: 99%

“…14 In addition, eIF4E promotes mRNA capping efficiency and increases cap structure mRNAs' stability. 15 eIF4E is upregulated in many tumours [16][17][18] and is an important oncogenic factor with therapeutic promise. eIF4E's only known post-translational modification is phosphorylation at its S209 site, downstream of MNK1/2.…”

mentioning

confidence: 99%

eIF4E plays the role of a pathogenic gene in psoriasis, and the inhibition of eIF4E phosphorylation ameliorates psoriasis‐like skin damage

Wang,

Yang,

Zhen

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

Psoriasis is a complex inflammatory skin disease with uncertain pathogenesis. eIF4E (eukaryotic translation initiation factor 4E) and its phosphorylation state p‐eIF4E are highly expressed in psoriatic tissues. However, the role eIF4E played in psoriasis is still unclear. To investigate the function of eIF4E and p‐eIF4E in psoriasis and to figure out whether eFT‐508 (Tomivosertib, eIF4E phosphorylation inhibitor) can relieve the disease severity and become a promising candidate for the psoriasis treatment. We first verified the expression of eIF4E and p‐eIF4E in psoriasis patients' lesional skin. Then, we demonstrated the effect of eIF4E and p‐eIF4E on the abnormal proliferation and inflammatory state of keratinocytes by using eIF4E‐specific small interfering RNA (si‐eIF4E) and eFT‐508. In this study, all cell experiments were performed under the psoriasis‐model condition. Moreover, the external application of eFT‐508 on imiquimod (IMQ)‐induced psoriasis mice was performed to explore its potential clinical value. Results showed that eIF4E and p‐eIF4E were significantly overexpressed in skin lesions of psoriasis patients. Knocking down eIF4E or adding eFT‐508 can relieve the abnormal proliferation and the excessive inflammatory state of keratinocytes by reducing the expression of cyclin D1, IL‐1β, CXCL10, IL23, Wnt 5a, NBS1 and p‐AKT from mRNA or protein levels. Furthermore, these results were consistent with those obtained from the in vitro experiments. Then, we conclude that eIF4E plays the role of the pathogenic gene in psoriasis, and eFT‐508 may be a promising candidate for anti‐prosoriasis drugs.

show abstract

ROS regulation in gliomas: implications for treatment strategies

Yang,

Zhu,

Sun

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Gliomas are one of the most common primary malignant tumours of the central nervous system (CNS), of which glioblastomas (GBMs) are the most common and destructive type. The glioma tumour microenvironment (TME) has unique characteristics, such as hypoxia, the blood-brain barrier (BBB), reactive oxygen species (ROS) and tumour neovascularization. Therefore, the traditional treatment effect is limited. As cellular oxidative metabolites, ROS not only promote the occurrence and development of gliomas but also affect immune cells in the immune microenvironment. In contrast, either too high or too low ROS levels are detrimental to the survival of glioma cells, which indicates the threshold of ROS. Therefore, an in-depth understanding of the mechanisms of ROS production and scavenging, the threshold of ROS, and the role of ROS in the glioma TME can provide new methods and strategies for glioma treatment. Current methods to increase ROS include photodynamic therapy (PDT), sonodynamic therapy (SDT), and chemodynamic therapy (CDT), etc., and methods to eliminate ROS include the ingestion of antioxidants. Increasing/scavenging ROS is potentially applicable treatment, and further studies will help to provide more effective strategies for glioma treatment.

show abstract

Expression of eIF4E Gene in Glioma and Its Sensitivity to Oxidative Stress

Cited by 3 publications

References 49 publications

The dark side of mRNA translation and the translation machinery in glioblastoma

The dark side of mRNA translation and the translation machinery in glioblastoma

eIF4E plays the role of a pathogenic gene in psoriasis, and the inhibition of eIF4E phosphorylation ameliorates psoriasis‐like skin damage

ROS regulation in gliomas: implications for treatment strategies

Contact Info

Product

Resources

About